Back to News
Market Impact: 0.38
Adagene Gains NMPA Clearance On Phase 1 For ADG138 In Solid Tumors, Set To Begin In Q4 '26
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Adagene received NMPA clearance in China for its investigational new drug application for ADG138 to treat solid tumors. The authorization enables clinical development of the oncology candidate in China and is a positive pipeline milestone for the clinical-stage biotech.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
ADAG0.72
More News
- Paramount will need to release way more movies to make this merger work
- Sullivan: Wall Street admits it doesn't know where oil is headed. There's one stock they do agree on
- U.S. regulators rush to write crypto rulebook after Clarity Act stalls in Senate
- We Want This Country to Win Tokenization: SEC's Selway
- Australia’s IDP shares drop after rejecting $494 mln Blackstone offer
- ACCC blocks IAG’s proposed acquisition of RAC Insurance
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- 2026 Global Markets Outlook: Asset Allocation After the Great Disconnect
- Fintool Alternatives After the Microsoft Acquisition